ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,347.40
0.45%
S&P ASX All Technology
3,799.90
0.91%
Brent Oil
79.30
-1.14%
US Dollar vs AUD
1.59787
-1.01%
Bitcoin
103,092.06
-0.05%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. ADC Therapeutics SA (ADCT) Share Price

ADC Therapeutics SA

ADC Therapeutics SA (ADCT)

NYSE
1.83
0.08
(4.57%)
Closed 21 January 8:00AM
Delayed by 15 minutes
1.74
-0.09
(-4.92%)
After Hours: 11:59AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.74
Bid
-
Offer
-
Volume
549,040
1.73 Day's Range 1.84
1.675 52 Week Range 6.04
Market Cap
168.24M
Previous Close
1.75
Open
1.80
Last Trade
110
@
1.74
(formt)
Last Trade Time
Financial Volume
US$ 977,014
VWAP
1.7795
Average Volume (3m)
937,393
Shares Outstanding
96,689,617
Dividend Yield
-
PE Ratio
-0.75
Earnings Per Share (EPS)
-2.43
Revenue
69.56M
Net Profit
-234.53M

About ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more

Sector
Drugs And Proprietary-whsl
Industry
Drugs And Proprietary-whsl
Website
www.adctherapeutics.com
Headquarters
Lausanne, Che
Founded
-
ADC Therapeutics SA is listed in the Drugs And Proprietary-whsl sector of the New York Stock Exchange with ticker ADCT. The last closing price for ADC Therapeutics was US$1.75. Over the last year, ADC Therapeutics shares have traded in a share price range of US$ 1.675 to US$ 6.04.

ADC Therapeutics currently has 96,689,617 shares in issue. The market capitalisation of ADC Therapeutics is US$169.21 million. ADC Therapeutics has a price to earnings ratio (PE ratio) of -0.75.

Ask ADVFN Intelligence (AI)

ADCT Latest News

More News

Form 8-K - Current report

14 January 2025
Edgar (US Regulatory)

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Jan. 2, 2025 LAUSANNE, Switzerland, Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:...

03 January 2025
PR Newswire (US)

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma PR Newswire LAUSANNE...

31 December 2024
PR Newswire (US)

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell...

11 December 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

10 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 December 2024
Edgar (US Regulatory)

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular...

09 December 2024
PR Newswire (US)

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial PR Newswire LAUSANNE, Switzerland, Dec. 6, 2024 Company to host corporate update webcast to share results on December 11...

06 December 2024
PR Newswire (US)

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Dec. 2, 2024 LAUSANNE, Switzerland, Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:...

03 December 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.128-6.8522483941.8681.91.6755412851.77863033CS
4-0.33-15.94202898552.072.1951.6757106551.93960654CS
12-1.17-40.2061855672.913.491.6759373932.45943069CS
26-2.26-56.544.11.6756158022.66697323CS
52-0.15-7.936507936511.896.041.6756927473.3138675CS
156-15.19-89.722386296516.9317.890.3599085342033.59744156CS
260-28.26-94.23056.58990.3599084303798.94679918CS

ADCT - Frequently Asked Questions (FAQ)

What is the current ADC Therapeutics share price?
The current share price of ADC Therapeutics is US$ 1.74
How many ADC Therapeutics shares are in issue?
ADC Therapeutics has 96,689,617 shares in issue
What is the market cap of ADC Therapeutics?
The market capitalisation of ADC Therapeutics is USD 169.21M
What is the 1 year trading range for ADC Therapeutics share price?
ADC Therapeutics has traded in the range of US$ 1.675 to US$ 6.04 during the past year
What is the PE ratio of ADC Therapeutics?
The price to earnings ratio of ADC Therapeutics is -0.75
What is the cash to sales ratio of ADC Therapeutics?
The cash to sales ratio of ADC Therapeutics is 2.54
What is the reporting currency for ADC Therapeutics?
ADC Therapeutics reports financial results in USD
What is the latest annual turnover for ADC Therapeutics?
The latest annual turnover of ADC Therapeutics is USD 69.56M
What is the latest annual profit for ADC Therapeutics?
The latest annual profit of ADC Therapeutics is USD -234.53M
What is the registered address of ADC Therapeutics?
The registered address for ADC Therapeutics is ROUTE DE LA CORNICHE 3B, LAUSANNE, 1066
What is the ADC Therapeutics website address?
The website address for ADC Therapeutics is www.adctherapeutics.com
Which industry sector does ADC Therapeutics operate in?
ADC Therapeutics operates in the DRUGS AND PROPRIETARY-WHSL sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ARLAmerican Realty Investors Inc
US$ 15.93
(15.02%)
10.76k
RBOTVicarious Surgical Inc
US$ 16.382
(14.88%)
52.57k
AUNAAuna SA
US$ 8.45
(14.81%)
233.16k
MYTEMYT Netherlands Parent BV
US$ 9.45
(12.23%)
354.61k
BKSYBlackSky Technology Inc
US$ 11.71
(12.06%)
1.7M
SESSES AI Corporation
US$ 0.9369
(-9.91%)
51.58M
DMDesktop Metal Inc
US$ 2.19
(-9.88%)
547.32k
JKSJinkosolar Holdings Co Ltd
US$ 21.23
(-9.81%)
1.55M
BODIBeachbody Company Inc
US$ 6.60
(-9.59%)
19.82k
QBTSD Wave Quantum Inc
US$ 5.275
(-9.21%)
76.53M
QBTSD Wave Quantum Inc
US$ 5.275
(-9.21%)
76.53M
FFord Motor Company
US$ 10.18
(1.70%)
60.8M
BBDBanco Bradesco SA
US$ 1.96
(-1.01%)
59.92M
VALEVale SA
US$ 8.94
(1.94%)
59.4M
SESSES AI Corporation
US$ 0.9369
(-9.91%)
51.58M

ADCT Discussion

View Posts
Jab44 Jab44 1 month ago
Now under $2
👍️0
Jab44 Jab44 1 month ago
I guess regardless of how Ron Square and company are excited by the strong results of Lotis the street gives it a thumbs down.
👍️0
glenn1919 glenn1919 1 month ago
ADCT...................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
Jab44 Jab44 1 month ago
Nice move this morning . Hopefully good news with Lotis-7 clinical trial.
👍️0
Jab44 Jab44 2 months ago
This stock is an utter mess. Good news is needed soon or it will be under $1.50
👍️0
Monksdream Monksdream 5 months ago
ADCT under $3
👍️0
glenn1919 glenn1919 6 months ago
ADCT....................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
PonkenPlonken PonkenPlonken 7 months ago
Somethings very right here. Looking for 5+
👍️0
glenn1919 glenn1919 7 months ago
ADCT......................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
ADCT...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
ADCT MASSIVE BREAK OUT HERE
👍️0
glenn1919 glenn1919 11 months ago
ADCT..................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 11 months ago
ADCT new 52 week high
👍️0
Monksdream Monksdream 11 months ago
ADCT new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
Brilliantly played to 4.80. Precision technical charting.
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
ADCT...TARGET COMING IN
👍️0
glenn1919 glenn1919 11 months ago
ADCT......................................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
ADCT monster
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
ADCT...4.82 NEXT
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
ADCT..WAITED TOO LOG TO ENTER THIS BEAST!!!!
👍️0
glenn1919 glenn1919 12 months ago
ADCT.......................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 12 months ago
ADCT.................................................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT.........................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT...........................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT......................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT.........................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT.....................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
glenn1919 glenn1919 1 year ago
ADCT.......................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low

👍️0
Monksdream Monksdream 1 year ago
ADTC new 52 week low
👍️0
tw0122 tw0122 2 years ago
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
👍️0
81vette 81vette 2 years ago
Ripe for merger/buyout/Big Bang boom
👍️0
81vette 81vette 2 years ago
Revenue increased yoy,profits increase yoy,tons of cash on hand,the more I dig the more I confident I am, (usually more digging,less liking)
👍️0
81vette 81vette 2 years ago
$3.3m print and $760k omg,FOLLOW THE $ is the saying
👍️0
81vette 81vette 2 years ago
Great company,I loaded 2tons today lots of institutional buying and insiders have lots of skin in it,28 patents pending for awhile,many should be getting approved soon.macd crossed to bulls on March 27th,I am following the $,3 times it crossed in last year period,every time a run continued for many days,low risk high reward babe
👍️ 1
conix conix 2 years ago
ADCT in Seeking Alpha

https://seekingalpha.com/article/4561171-adc-therapeutics-running-through-bad-luck?
👍️0
north40000 north40000 3 years ago
https://ih.advfn.com/stock-market/NYSE/adc-therapeutics-ADCT/stock-news/87749724/adc-therapeutics-obtient-un-code-j-permanent-pour
👍️0
ibelurkin ibelurkin 4 years ago
FDA approves ADC's biologic Zynlonta for B-cell lymphom

👍️0
stockguard stockguard 4 years ago
ADC Therapeutics SA
Cowen healthcare conference: March 4th, 2021

https://wsw.com/webcast/cowen81/adct/1925484
👍️0
~WAVE~ ~WAVE~ 15 years ago
Great News! A Buyout!
The Stock Compound Called It!
👍️0
~WAVE~ ~WAVE~ 15 years ago
ADCT got called this morning on The Stock Compound's scan.
stockcompound.blogspot.com/

That pays for my membership fee!
👍️0
zomniac zomniac 15 years ago
Whoaaa
What's happening ???
👍️0
mlkrborn mlkrborn 15 years ago
DC Telecommunications (ADCT Quote) rallied by 80 cents, or 14.9%, to $6.18 after the broadband communications provider said late Monday it had a fiscal first-quarter profit of 2 cents, better than analysts' expectations that ADC would break even in the quarter. ADC also offered in-line earnings and revenue guidance for its fiscal second quarter. Volume topped 5.71 million shares, compared to the 50-day average daily volume of 2.07 million, according to the Nasdaq.
👍️0
OldAIMGuy OldAIMGuy 17 years ago
Nice uptick in ADCT today. Earnings and sales are up on the most recent report.

Best regards, Tom
👍️0

Your Recent History

NYSE
ADCT
ADC Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads